Amicus Therapeutics (NASDAQ:FOLD) PT Raised to $15.00 at Bank of America

Amicus Therapeutics (NASDAQ:FOLD) had its price objective upped by Bank of America from $13.00 to $15.00 in a report published on Thursday, Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

A number of other equities analysts also recently issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 price target on shares of Amicus Therapeutics in a research note on Friday, September 20th. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a report on Friday, August 9th. StockNews.com cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 15th. Morgan Stanley reduced their target price on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating on the stock in a research report on Friday, August 16th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $17.13.

Amicus Therapeutics Trading Down 0.6 %

NASDAQ FOLD opened at $11.90 on Thursday. The company has a quick ratio of 2.26, a current ratio of 2.75 and a debt-to-equity ratio of 2.93. Amicus Therapeutics has a 52 week low of $9.02 and a 52 week high of $14.57. The business has a 50 day moving average price of $11.17 and a 200-day moving average price of $10.56. The company has a market cap of $3.52 billion, a price-to-earnings ratio of -24.29 and a beta of 0.69.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05). Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The business had revenue of $126.67 million during the quarter, compared to analyst estimates of $121.21 million. During the same quarter in the previous year, the business posted ($0.15) EPS. Amicus Therapeutics’s quarterly revenue was up 34.0% on a year-over-year basis. As a group, equities analysts expect that Amicus Therapeutics will post -0.07 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $11.71, for a total transaction of $87,825.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $10,382,718.34. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders have sold 22,500 shares of company stock valued at $244,875. 2.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Amicus Therapeutics

Large investors have recently added to or reduced their stakes in the company. Blue Trust Inc. boosted its position in Amicus Therapeutics by 1,705.4% during the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,831 shares during the period. Headlands Technologies LLC purchased a new position in Amicus Therapeutics in the 2nd quarter valued at approximately $89,000. Sage Capital Advisors llc purchased a new position in Amicus Therapeutics in the 2nd quarter valued at approximately $103,000. Sanctuary Advisors LLC bought a new stake in Amicus Therapeutics during the 2nd quarter valued at $138,000. Finally, EntryPoint Capital LLC lifted its position in shares of Amicus Therapeutics by 278.8% during the first quarter. EntryPoint Capital LLC now owns 13,218 shares of the biopharmaceutical company’s stock worth $156,000 after acquiring an additional 9,729 shares in the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.